An interventional study of Dienogest group and Gestodene-Ethinyl Estradiol in Adenomyosis, sponsored by Assiut University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-08-25.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure this disease. Other treatment options are increasingly offered, including hormonal suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation. However, deep adenomyosis responds weakly to the above treatment options, which are commonly not considered for long-term management because of the associated side effects.
Dienogest is a progestin medication which is used in birth control pills and in the treatment of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been widely used as the primary treatment for menorrhagia. COCs can also be used to induce endometrial atrophy and to decrease endometrial prostaglandin production, which can consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis
135 studies on the registry are indexed under Adenomyosis; 50 are open to participants now.
This study's enrollment of 100 is close to the median of 100 across 73 interventional studies indexed under Adenomyosis.
Browse Adenomyosis studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Dienogest group · Radiation: Ultrasound · Other: visual analogue scale
Drug: Gestodene-Ethinyl Estradiol · Radiation: Ultrasound · Other: visual analogue scale
VISANNE 2MG Tablet once daily
Gynera tablet once daily
ultrasound assessment of uterine volume
visual analogue scale for assessment of pain
Number of women who will improved from the pelvic pain measured by visual analogue scale
Time frame: 6 months
Uterine volume (cm 3 ) measure by ultrasound
Time frame: 6 month
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University